Cite
HARVARD Citation
Neoptolemos, J. et al. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 389 (10073), pp. 1011-1024. [Online].